Anne Lynch
Concepts (320)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 14 | 2026 | 183 | 5.490 |
Why?
| | Macular Degeneration | 15 | 2026 | 196 | 4.110 |
Why?
| | Geographic Atrophy | 13 | 2026 | 105 | 3.510 |
Why?
| | Wet Macular Degeneration | 8 | 2026 | 63 | 2.750 |
Why?
| | Visual Acuity | 21 | 2026 | 499 | 2.250 |
Why?
| | Birth Weight | 11 | 2024 | 521 | 2.100 |
Why?
| | Complement Factor B | 7 | 2022 | 106 | 2.090 |
Why?
| | Complement Activation | 8 | 2025 | 412 | 1.960 |
Why?
| | Pre-Eclampsia | 8 | 2024 | 206 | 1.560 |
Why?
| | Neonatal Screening | 5 | 2022 | 185 | 1.530 |
Why?
| | Gestational Age | 17 | 2026 | 990 | 1.480 |
Why?
| | Retinal Drusen | 3 | 2024 | 31 | 1.480 |
Why?
| | Cataract | 12 | 2024 | 240 | 1.480 |
Why?
| | Tomography, Optical Coherence | 11 | 2026 | 283 | 1.360 |
Why?
| | Premature Birth | 5 | 2017 | 390 | 1.290 |
Why?
| | Registries | 11 | 2025 | 2400 | 1.110 |
Why?
| | Phacoemulsification | 8 | 2023 | 124 | 1.100 |
Why?
| | Fluorescein Angiography | 8 | 2026 | 197 | 1.060 |
Why?
| | Infant, Premature | 7 | 2024 | 622 | 1.000 |
Why?
| | Complement C3a | 2 | 2019 | 40 | 0.930 |
Why?
| | Cataract Extraction | 7 | 2024 | 120 | 0.840 |
Why?
| | Diseases in Twins | 1 | 2024 | 115 | 0.810 |
Why?
| | Infant, Newborn | 17 | 2026 | 6460 | 0.810 |
Why?
| | Twins | 1 | 2024 | 156 | 0.800 |
Why?
| | Risk Factors | 23 | 2025 | 10921 | 0.780 |
Why?
| | Retrospective Studies | 40 | 2026 | 17438 | 0.780 |
Why?
| | Diabetic Retinopathy | 5 | 2023 | 211 | 0.750 |
Why?
| | Pregnancy | 25 | 2024 | 7230 | 0.660 |
Why?
| | Weight Gain | 4 | 2019 | 562 | 0.630 |
Why?
| | Female | 73 | 2026 | 79499 | 0.620 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 147 | 0.610 |
Why?
| | Humans | 94 | 2026 | 146342 | 0.610 |
Why?
| | Infant, Low Birth Weight | 2 | 2017 | 154 | 0.590 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 38 | 0.580 |
Why?
| | Biomarkers | 12 | 2026 | 4340 | 0.570 |
Why?
| | Follow-Up Studies | 18 | 2026 | 5439 | 0.570 |
Why?
| | Cohort Studies | 11 | 2024 | 6077 | 0.560 |
Why?
| | Pregnancy Outcome | 7 | 2015 | 503 | 0.560 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 57 | 0.560 |
Why?
| | Internet | 1 | 2023 | 660 | 0.550 |
Why?
| | Aged, 80 and over | 20 | 2026 | 8391 | 0.540 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 2024 | 427 | 0.530 |
Why?
| | Complement System Proteins | 4 | 2026 | 326 | 0.530 |
Why?
| | Labor, Induced | 2 | 2017 | 41 | 0.520 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 195 | 0.510 |
Why?
| | Colorado | 12 | 2025 | 4595 | 0.510 |
Why?
| | Algorithms | 6 | 2018 | 1849 | 0.510 |
Why?
| | Diagnostic Techniques, Ophthalmological | 2 | 2018 | 55 | 0.490 |
Why?
| | Labor, Obstetric | 1 | 2017 | 67 | 0.490 |
Why?
| | Retinal Detachment | 3 | 2023 | 74 | 0.490 |
Why?
| | Blood Proteins | 2 | 2015 | 239 | 0.480 |
Why?
| | Aged | 30 | 2026 | 26432 | 0.470 |
Why?
| | Intraocular Pressure | 5 | 2024 | 344 | 0.460 |
Why?
| | Pregnancy Trimester, First | 2 | 2015 | 140 | 0.450 |
Why?
| | Male | 48 | 2026 | 73396 | 0.440 |
Why?
| | Refraction, Ocular | 4 | 2024 | 47 | 0.440 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 320 | 0.430 |
Why?
| | Choroid | 2 | 2025 | 81 | 0.410 |
Why?
| | Infant, Very Low Birth Weight | 4 | 2019 | 74 | 0.400 |
Why?
| | Infant | 13 | 2026 | 10114 | 0.400 |
Why?
| | Angiogenesis Inhibitors | 3 | 2026 | 239 | 0.390 |
Why?
| | Multimodal Imaging | 2 | 2025 | 137 | 0.390 |
Why?
| | Disease Progression | 8 | 2026 | 2867 | 0.390 |
Why?
| | Placenta | 2 | 2018 | 794 | 0.380 |
Why?
| | Photorefractive Keratectomy | 2 | 2024 | 21 | 0.380 |
Why?
| | Keratomileusis, Laser In Situ | 2 | 2024 | 20 | 0.380 |
Why?
| | Intraoperative Complications | 4 | 2022 | 157 | 0.380 |
Why?
| | Myopia | 3 | 2024 | 59 | 0.370 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2012 | 162 | 0.370 |
Why?
| | Inflammation | 4 | 2023 | 2919 | 0.370 |
Why?
| | Research Design | 1 | 2019 | 1143 | 0.370 |
Why?
| | Vitrectomy | 3 | 2021 | 74 | 0.350 |
Why?
| | Logistic Models | 9 | 2024 | 2126 | 0.350 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 10 | 0.350 |
Why?
| | Laser Coagulation | 2 | 2026 | 80 | 0.340 |
Why?
| | Cesarean Section | 3 | 2011 | 230 | 0.340 |
Why?
| | Odds Ratio | 5 | 2019 | 1077 | 0.340 |
Why?
| | Lens Implantation, Intraocular | 4 | 2022 | 80 | 0.330 |
Why?
| | Retinal Diseases | 2 | 2023 | 102 | 0.330 |
Why?
| | Body Mass Index | 4 | 2014 | 2458 | 0.330 |
Why?
| | Prospective Studies | 16 | 2026 | 8123 | 0.320 |
Why?
| | Complement Activating Enzymes | 1 | 2010 | 3 | 0.310 |
Why?
| | Pregnancy Complications | 3 | 2010 | 609 | 0.300 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2012 | 438 | 0.300 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 74 | 0.300 |
Why?
| | Influenza Vaccines | 2 | 2012 | 544 | 0.290 |
Why?
| | Immunologic Factors | 2 | 2022 | 244 | 0.270 |
Why?
| | Complement Pathway, Alternative | 2 | 2013 | 123 | 0.270 |
Why?
| | Influenza, Human | 2 | 2012 | 640 | 0.270 |
Why?
| | Obesity | 3 | 2014 | 3131 | 0.260 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2019 | 846 | 0.260 |
Why?
| | Antibodies, Antiphospholipid | 3 | 1999 | 29 | 0.260 |
Why?
| | Receptors, Cell Surface | 1 | 2010 | 371 | 0.260 |
Why?
| | Adult | 25 | 2025 | 41087 | 0.260 |
Why?
| | Lenses, Intraocular | 3 | 2022 | 49 | 0.260 |
Why?
| | Sensitivity and Specificity | 3 | 2017 | 1998 | 0.250 |
Why?
| | Lasers, Excimer | 2 | 2024 | 30 | 0.250 |
Why?
| | Antigens, CD | 1 | 2010 | 560 | 0.240 |
Why?
| | Fovea Centralis | 1 | 2025 | 24 | 0.230 |
Why?
| | Acanthamoeba Keratitis | 1 | 2025 | 4 | 0.230 |
Why?
| | Case-Control Studies | 7 | 2022 | 3647 | 0.230 |
Why?
| | Eye Infections, Parasitic | 1 | 2025 | 6 | 0.230 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 40 | 0.220 |
Why?
| | Corneal Transplantation | 2 | 2025 | 17 | 0.220 |
Why?
| | Incidence | 4 | 2022 | 2936 | 0.220 |
Why?
| | Time Factors | 5 | 2025 | 7109 | 0.220 |
Why?
| | Glaucoma | 2 | 2018 | 267 | 0.210 |
Why?
| | Middle Aged | 22 | 2026 | 36619 | 0.210 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2011 | 1408 | 0.200 |
Why?
| | Diabetes Mellitus | 2 | 2023 | 1101 | 0.200 |
Why?
| | Membrane Proteins | 1 | 2010 | 1130 | 0.190 |
Why?
| | Vitreous Body | 2 | 2022 | 118 | 0.190 |
Why?
| | Surveys and Questionnaires | 8 | 2026 | 6073 | 0.190 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2024 | 69 | 0.190 |
Why?
| | Methylprednisolone | 1 | 2023 | 58 | 0.190 |
Why?
| | Optic Neuritis | 1 | 2023 | 44 | 0.190 |
Why?
| | Vision, Low | 1 | 2022 | 16 | 0.190 |
Why?
| | Postoperative Complications | 5 | 2023 | 3034 | 0.180 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1543 | 0.180 |
Why?
| | Vaccination | 1 | 2011 | 1449 | 0.180 |
Why?
| | Retinal Perforations | 1 | 2022 | 18 | 0.180 |
Why?
| | Quality of Life | 6 | 2026 | 3200 | 0.170 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 8 | 0.170 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.170 |
Why?
| | Capsule Opacification | 1 | 2021 | 22 | 0.170 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.170 |
Why?
| | Proteomics | 2 | 2020 | 1203 | 0.170 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.160 |
Why?
| | Aberrometry | 1 | 2020 | 9 | 0.160 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 124 | 0.160 |
Why?
| | Eye Banks | 1 | 2020 | 7 | 0.160 |
Why?
| | Fundus Oculi | 3 | 2025 | 89 | 0.160 |
Why?
| | Trabeculectomy | 2 | 2018 | 76 | 0.160 |
Why?
| | Optics and Photonics | 1 | 2020 | 38 | 0.160 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.160 |
Why?
| | Abortion, Spontaneous | 2 | 1999 | 120 | 0.160 |
Why?
| | United States | 9 | 2025 | 16136 | 0.160 |
Why?
| | Risk Assessment | 3 | 2019 | 3712 | 0.150 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5899 | 0.150 |
Why?
| | Scleral Buckling | 1 | 2019 | 16 | 0.150 |
Why?
| | Macula Lutea | 1 | 2019 | 21 | 0.150 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 29 | 0.150 |
Why?
| | Hepatitis C | 1 | 2022 | 251 | 0.150 |
Why?
| | Strabismus | 1 | 2020 | 71 | 0.150 |
Why?
| | Laser Therapy | 1 | 2021 | 146 | 0.150 |
Why?
| | Oculomotor Muscles | 1 | 2020 | 86 | 0.150 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2020 | 91 | 0.150 |
Why?
| | Dementia | 1 | 2023 | 324 | 0.140 |
Why?
| | Dermatitis, Atopic | 1 | 2022 | 319 | 0.140 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 12 | 0.140 |
Why?
| | Homosexuality, Male | 1 | 2020 | 231 | 0.140 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 144 | 0.140 |
Why?
| | Pilocarpine | 1 | 2018 | 16 | 0.140 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 18 | 0.140 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 1999 | 83 | 0.140 |
Why?
| | Ophthalmic Solutions | 1 | 2018 | 82 | 0.130 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 23 | 0.130 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2623 | 0.130 |
Why?
| | Trabecular Meshwork | 1 | 2018 | 74 | 0.130 |
Why?
| | Metformin | 1 | 2021 | 328 | 0.130 |
Why?
| | Ocular Hypertension | 1 | 2018 | 72 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 474 | 0.130 |
Why?
| | Young Adult | 9 | 2025 | 14330 | 0.130 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 18 | 0.120 |
Why?
| | Parity | 1 | 2017 | 113 | 0.120 |
Why?
| | Glycoproteins | 1 | 1999 | 356 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2026 | 545 | 0.120 |
Why?
| | Glaucoma, Open-Angle | 1 | 2018 | 109 | 0.120 |
Why?
| | Automobile Driving | 1 | 2018 | 157 | 0.120 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2016 | 24 | 0.120 |
Why?
| | Tonometry, Ocular | 3 | 2024 | 107 | 0.120 |
Why?
| | Fetus | 2 | 2018 | 800 | 0.120 |
Why?
| | Risk | 1 | 2018 | 920 | 0.110 |
Why?
| | Time-to-Pregnancy | 1 | 2015 | 3 | 0.110 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2921 | 0.110 |
Why?
| | Recovery of Function | 1 | 2019 | 725 | 0.110 |
Why?
| | Treatment Outcome | 7 | 2026 | 11821 | 0.110 |
Why?
| | Phenotype | 2 | 2022 | 3206 | 0.100 |
Why?
| | Proteins | 1 | 2020 | 1022 | 0.100 |
Why?
| | Mothers | 2 | 2018 | 772 | 0.100 |
Why?
| | Self Report | 1 | 2018 | 870 | 0.100 |
Why?
| | Sickness Impact Profile | 2 | 2026 | 67 | 0.100 |
Why?
| | Obstetric Labor, Premature | 1 | 2013 | 39 | 0.100 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2017 | 295 | 0.100 |
Why?
| | Intravitreal Injections | 2 | 2026 | 73 | 0.100 |
Why?
| | Cervical Ripening | 1 | 2013 | 9 | 0.100 |
Why?
| | Cervix Uteri | 1 | 2013 | 50 | 0.090 |
Why?
| | Uterine Hemorrhage | 1 | 2013 | 41 | 0.090 |
Why?
| | Sulfonamides | 1 | 2016 | 594 | 0.090 |
Why?
| | Models, Statistical | 1 | 2016 | 669 | 0.090 |
Why?
| | Pulmonary Fibrosis | 2 | 2008 | 395 | 0.090 |
Why?
| | Axial Length, Eye | 2 | 2024 | 17 | 0.090 |
Why?
| | Aspirin | 1 | 2015 | 405 | 0.090 |
Why?
| | Fetal Blood | 1 | 2013 | 325 | 0.080 |
Why?
| | Autoantibodies | 1 | 1999 | 1500 | 0.080 |
Why?
| | Infant, Small for Gestational Age | 1 | 2012 | 118 | 0.080 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2015 | 499 | 0.080 |
Why?
| | Endoglin | 1 | 2010 | 19 | 0.080 |
Why?
| | Hypertension | 1 | 1999 | 1272 | 0.080 |
Why?
| | Adiposity | 1 | 2014 | 533 | 0.080 |
Why?
| | Cesarean Section, Repeat | 1 | 2009 | 11 | 0.070 |
Why?
| | Intensive Care, Neonatal | 1 | 2009 | 41 | 0.070 |
Why?
| | Postoperative Period | 2 | 2020 | 355 | 0.070 |
Why?
| | Placental Insufficiency | 1 | 2010 | 126 | 0.070 |
Why?
| | Child | 4 | 2022 | 22693 | 0.070 |
Why?
| | Models, Biological | 1 | 2016 | 1761 | 0.070 |
Why?
| | Seasons | 1 | 2011 | 540 | 0.070 |
Why?
| | Pregnancy Trimester, Third | 1 | 2008 | 117 | 0.070 |
Why?
| | Heart Rate | 1 | 2012 | 846 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2022 | 561 | 0.070 |
Why?
| | Longitudinal Studies | 2 | 2026 | 3017 | 0.070 |
Why?
| | Health Status Disparities | 1 | 2011 | 322 | 0.060 |
Why?
| | Elective Surgical Procedures | 1 | 2009 | 216 | 0.060 |
Why?
| | ROC Curve | 2 | 2019 | 617 | 0.060 |
Why?
| | Patient Compliance | 1 | 2011 | 589 | 0.060 |
Why?
| | Glyburide | 1 | 2006 | 30 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2026 | 1331 | 0.060 |
Why?
| | Resuscitation | 1 | 2009 | 314 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3930 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2008 | 2113 | 0.060 |
Why?
| | Bevacizumab | 1 | 2026 | 169 | 0.060 |
Why?
| | Blood Pressure | 1 | 2012 | 1765 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2008 | 2786 | 0.050 |
Why?
| | Ultrasonography, Doppler | 1 | 2005 | 122 | 0.050 |
Why?
| | Papanicolaou Test | 1 | 2004 | 35 | 0.050 |
Why?
| | Vaginal Smears | 1 | 2004 | 54 | 0.050 |
Why?
| | Urban Health | 1 | 2004 | 95 | 0.050 |
Why?
| | Fetal Growth Retardation | 2 | 2012 | 592 | 0.050 |
Why?
| | Hypoglycemic Agents | 2 | 2021 | 1412 | 0.050 |
Why?
| | Contraceptives, Oral, Combined | 1 | 2004 | 18 | 0.050 |
Why?
| | Uterus | 1 | 2005 | 227 | 0.050 |
Why?
| | Refractive Errors | 1 | 2024 | 36 | 0.050 |
Why?
| | Adolescent | 6 | 2025 | 22557 | 0.050 |
Why?
| | Hospitals, County | 1 | 2023 | 11 | 0.050 |
Why?
| | Ovarian Follicle | 1 | 2004 | 78 | 0.050 |
Why?
| | Prevalence | 2 | 2024 | 2861 | 0.050 |
Why?
| | Retinal Pigment Epithelium | 1 | 2024 | 81 | 0.050 |
Why?
| | Double-Blind Method | 4 | 2015 | 2070 | 0.050 |
Why?
| | Length of Stay | 1 | 2009 | 1358 | 0.050 |
Why?
| | Neuroprotection | 1 | 2023 | 46 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2011 | 1591 | 0.050 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 145 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 207 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 41 | 0.040 |
Why?
| | Pandemics | 1 | 2011 | 1707 | 0.040 |
Why?
| | Diabetes, Gestational | 1 | 2006 | 307 | 0.040 |
Why?
| | Alanine Transaminase | 1 | 2022 | 151 | 0.040 |
Why?
| | Albumins | 1 | 2022 | 120 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 182 | 0.040 |
Why?
| | Cornea | 1 | 2022 | 156 | 0.040 |
Why?
| | Hepacivirus | 1 | 2022 | 237 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 69 | 0.040 |
Why?
| | Vision Disorders | 1 | 2022 | 179 | 0.040 |
Why?
| | Myotomy | 1 | 2020 | 15 | 0.040 |
Why?
| | Vision, Binocular | 1 | 2020 | 47 | 0.040 |
Why?
| | Eye Movements | 1 | 2020 | 92 | 0.040 |
Why?
| | Growth Charts | 1 | 2019 | 20 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 97 | 0.040 |
Why?
| | HIV | 1 | 2020 | 249 | 0.040 |
Why?
| | beta 2-Glycoprotein I | 1 | 1999 | 5 | 0.040 |
Why?
| | Canada | 1 | 2020 | 432 | 0.040 |
Why?
| | Antibodies, Anticardiolipin | 1 | 1999 | 7 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2019 | 39 | 0.040 |
Why?
| | Pulmonary Gas Exchange | 1 | 1999 | 117 | 0.040 |
Why?
| | Anthropometry | 1 | 2019 | 204 | 0.040 |
Why?
| | Phosphatidylserines | 1 | 1999 | 62 | 0.040 |
Why?
| | Area Under Curve | 1 | 2019 | 335 | 0.040 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.030 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 16 | 0.030 |
Why?
| | Pseudophakia | 1 | 2018 | 21 | 0.030 |
Why?
| | Confidence Intervals | 1 | 1999 | 329 | 0.030 |
Why?
| | Positive-Pressure Respiration | 1 | 1999 | 115 | 0.030 |
Why?
| | Bronchodilator Agents | 1 | 1999 | 186 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2004 | 881 | 0.030 |
Why?
| | Family | 1 | 2022 | 690 | 0.030 |
Why?
| | Physical Examination | 1 | 2019 | 237 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 1999 | 284 | 0.030 |
Why?
| | Child, Preschool | 3 | 2022 | 11913 | 0.030 |
Why?
| | North America | 1 | 2018 | 300 | 0.030 |
Why?
| | Equipment Design | 1 | 2018 | 520 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 801 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2022 | 881 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 779 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 1068 | 0.030 |
Why?
| | Interferon-beta | 2 | 2008 | 90 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 1999 | 330 | 0.030 |
Why?
| | Plethysmography | 1 | 2014 | 104 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 1999 | 901 | 0.030 |
Why?
| | Apgar Score | 1 | 1994 | 20 | 0.030 |
Why?
| | Nitric Oxide | 1 | 1999 | 883 | 0.030 |
Why?
| | Respiratory Function Tests | 2 | 2008 | 543 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2022 | 2012 | 0.020 |
Why?
| | Mice | 1 | 2010 | 18297 | 0.020 |
Why?
| | Linear Models | 1 | 2014 | 857 | 0.020 |
Why?
| | Treatment Failure | 2 | 2006 | 361 | 0.020 |
Why?
| | Organ Size | 1 | 2013 | 465 | 0.020 |
Why?
| | Maternal-Fetal Exchange | 1 | 2012 | 171 | 0.020 |
Why?
| | Body Composition | 1 | 2014 | 689 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2014 | 642 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1327 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2012 | 689 | 0.020 |
Why?
| | Animals | 1 | 2010 | 38107 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 517 | 0.020 |
Why?
| | Fetal Macrosomia | 1 | 2006 | 64 | 0.010 |
Why?
| | Rheology | 1 | 2005 | 94 | 0.010 |
Why?
| | Chicago | 1 | 2004 | 62 | 0.010 |
Why?
| | Survival Analysis | 1 | 2008 | 1378 | 0.010 |
Why?
| | Ethinyl Estradiol | 1 | 2004 | 16 | 0.010 |
Why?
| | Levonorgestrel | 1 | 2004 | 34 | 0.010 |
Why?
| | Desogestrel | 1 | 2004 | 46 | 0.010 |
Why?
| | Ultrasonography, Prenatal | 1 | 2005 | 291 | 0.010 |
Why?
| | Menstrual Cycle | 1 | 2004 | 145 | 0.010 |
Why?
| | Women's Health | 1 | 2004 | 317 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2004 | 790 | 0.010 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2004 | 269 | 0.010 |
Why?
| | Regression Analysis | 1 | 2003 | 999 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1999 | 567 | 0.010 |
Why?
| | Oxygen | 1 | 1999 | 997 | 0.010 |
Why?
| | Hypoxia | 1 | 1999 | 1211 | 0.010 |
Why?
|
|
Lynch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|